Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New kid on the block

This article was originally published in The Tan Sheet

Executive Summary

Dynova Laboratories enters the supplement market with the acquisition of SiCaps Industries and its capsaicin-based Sinus Buster brand products. Parsippany, N.J.-based Dynova, backed by the private equity fund Aisling Capital, looks to provide clinical, marketing, packaging and sales support to "novel" dietary supplement products and ingredients with "unique delivery" and "compelling claims," according to Dynova's Web site. The firm led by former Novartis OTC business executives Lynne Millheiser-Swanbeck and Jeff Vernimb, and by Jennifer Cooper, formerly with Twin Laboratories and Solgar...

You may also be interested in...



Turkish Medtechs Face The Constant Challenge Of Sailing In Stormy Seas

The pandemic has exacerbated the problems of the Turkish medical device industry, which was already struggling for survival and growth in a hostile policy environment. Local blood bag manufacturer Kansuk Laboratory talked to Medtech Insight about the difficulties it faces.

Pipeline Watch: Phase III Readouts For COVID-19, Dry Eye Disease, Uveal Melanoma

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Ireland’s Supply Chain Suffers Due To Brexit And Covid

Medicines for Ireland has released a report focusing on the direct impact of Brexit and COVID-19 on the medicines supply chain. The association has called for long-term plans and solutions instead of temporary fixes for issues related to delays in the import and export of medicines. 

Topics

UsernamePublicRestriction

Register

PS101894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel